Key clinical point: Paclitaxel dose exposure at the index procedure did not affect survival status in DCB patients through 5 years.

Major finding: There was no significant difference in all-cause mortality between DCB and PTA through five years (9.3% vs. 11.2%, respectively; P = .399).Study details: Meta-analysis of five clinical trials assessing 1,980 patients.

Disclosures: The study was funded by Medtronic, which provided the data for independent analysis to the Baim Institute for Clinical Research. Dr. Schneider is a member of the advisory board for Medtronic, Abbott, and Boston Scientific and is a consultant for Medtronic and other device companies. Coauthors had consulting, advisory board, or honoraria relationships with Medtronic and other device companies.